Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2015 Financial and Operating Results on March 29, 2016

CHARLESTON, S.C.--(BUSINESS WIRE)-- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) will announce its fourth quarter and full-year 2015 financial and operating results after market close on Tuesday, March 29, 2016. The Company will host a conference call and webcast to discuss these results on Wednesday, March 30, 2016 at 8:00 a.m. Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com, or by telephone using the following number: 201-689-8029, Confirmation #13632538. A replay of the webcast will also be available on the Company’s website for a period of 30 days.

For reference, the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the fourth quarter and full-year 2015, as well as the Company’s audited consolidated financial statements as at December 31, 2015, 2014 and 2013, can be found at www.aezsinc.com in the “Investors/Regulatory Filings” section.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160315005304/en/

Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
[email protected]

Source: Aeterna Zentaris Inc.

You May Also Be Interested In

• Paramount Global (PARA) and Skydance are closer to a merger - CNBC
• Adevinta (ASA) publishes its 2023 Annual Report
• PMD Device Solutions Publishes 2023 Annual Report